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We have previously demonstrated that tumor cells release membranous structures into
their extracellular environment, which are termed exosomes, microvesicles or extracellular
vesicles depending on specific characteristics, including size, composition and biogenesis
pathway. These cell-derived vesicles can exhibit an array of proteins, lipids and nucleic
acids derived from the originating tumor. This review focuses of the transcriptome (RNA)
of these extracellular vesicles. Based on current data, these vesicular components play
essential roles as conveyers of intercellular communication and mediators of many of the
pathological conditions associated with cancer development, progression and therapeutic
failures. These extracellular vesicles express components responsible for angiogenesis
promotion, stromal remodeling, signal pathway activation through growth factor/receptor
transfer, chemoresistance, and genetic exchange. These tumor-derived extracellular
vesicles not only to represent a central mediator of the tumor microenvironment, but
their presence in the peripheral circulation may serve as a surrogate for tumor biopsies,
enabling real-time diagnosis and disease monitoring.
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BACKGROUND
The release of 50–200 nm sized membranous vesicles into bio-
logical fluids by viable tumor cells was initially described by us
over three decades ago (Taylor and Doellgast, 1979) and has since
been demonstrated multiple cell types and systems. In vivo, these
nano-sized vesicles released by tumor cells accumulate in biologic
fluids, including blood,urine, ascites, and pleural fluids (Taylor
and Gercel-Taylor, 2011). The release and accumulation of these
extracellular vesicles appear to be important in the malignant
transformation process. Extracellular vesicles have been identified
by various terms, including high molecular weight complexes,
membrane fragments, exosomes, microvesicles, microparticles,
and extracellular vesicles. While more recently restrictive defi-
nitions have been applied to these cell-derived vesicles, signifi-
cant overlap (in terms of size, markers, cargoes, and function)
exists between structures identified as exosomes and microvesi-
cles. Within the circulation, it may not be possible to differentiate
50–100 nm “exosomes” from 50 to 200 nm “microvesicles.” In
many studies, uncharacterized cell-derived vesicles (in terms of
markers or size) are termed “microvesicles,” while numerous
studies define “exosomes” solely based on density and the pres-
ence of the cell surface markers, tetraspanins. These overlaps
in vesicle properties and terms suggest these distinctions may
not be clear-cut. For these reasons, this review uses the term
“extracellular vesicles” to include all 50–200 nm tumor-derived
vesicles.
The “exosome” term was coined in 1981 for “exfoliated mem-
brane vesicles with 5′-nucleotidase activity” (Trams et al., 1981).
This term, “exosome,” originated from the discovery of neo-
plastic cell line-derived exfoliated vesicles, which mirrored the
5′-nucleotidase activity of the parent cells (Trams et al., 1981).
Several years later, vesicles release via the canonical pathway
upon multi-vesicular endosome fusion with the cell surface
was demonstrated in cultured sheep (Pan et al., 1983) and
rat (Harding et al., 1983) reticulocytes. After purification by
ultracentrifugation, the pelleted vesicles were found to contain
the transferrin receptor that was also found in native reticu-
locytes (Johnstone et al., 1987). These reports proposed that
this represented a mechanism for the elimination of specific
cellular components as the reticulocytes matured and differ-
entiated. These cell-derived vesicles were redefined as “exo-
somes” to differentiate them from “endosomes.” The disparate
natures of these studies are reflected in the various names
that were proposed and which are still used to identify the
cell surface-released and endocytic vesicles of different ori-
gins. It is of noted that these later studies (Harding et al.,
1983; Pan et al., 1983; Johnstone et al., 1987) were exclusively
in vitro.
The in vivo appearance of tumor-derived vesicles within the
circulation was initially demonstrated in ovarian cancer patients
(Taylor and Doellgast, 1979; Taylor et al., 1980, 1983). These
gynecologic cancer patients exhibited intact extracellular vesi-
cles within their peripheral circulation and malignant effusions
(ascites and cyst fluids). These tumor-derived extracellular vesi-
cles were found to express molecular markers that were generally
linked with tumor plasma membranes, including placental type
alkaline phosphatase and mdr-1 (Taylor et al., 1985, 1989; Taylor
and Black, 1986); however, proteins not generally associated with
plasma membranes, such as p53, GRP78 and nucleophosmin,
were also identified with these circulating vesicles (Chinni et al.,
1997; Manahan et al., 2001).
Extracellular vesicles have since been demonstrated to be
released by a variety of non-cancerous cells, particularly cells
of the immune system, including dendritic cells, macrophages,
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B cells, T cells, and NK cells (Théry et al., 2009), as well as
embryonic cells (Atay et al., 2011a,b). These extracellular vesi-
cles have been demonstrated to be key mediators/regulators of
normal immune responses (Whiteside, 2013). One can view
tumors as a “cyber-terrorist” using these extracellular vesi-
cles to elicit aberrant immune regulation. Extracellular vesicles
released by the tumor may elicit a tolerogenic response and
participate in other immune mechanisms, such as platelet acti-
vation, mast cell degranulation, germinal center reaction, and
potential engulfment of apoptotic cells. The aberrant release of
extracellular vesicles by tumors may allow them to circumvent
these immunoregulatory antigen delivery pathways and evade
immunosurveillance (Taylor and Black, 1986; Taylor and Gercel-
Taylor, 2011).
EXTRACELLULAR VESICLES COMPOSITION AND
CHARACTERIZATION
Over the past three decades, shed tumor-derived vesicles have
been characterized for multiple human cancer types and they are
not exact replicates of the plasma membrane or other membra-
nous compartments of the originating tumor cells, but they rep-
resent “micromaps” with enhanced expression of tumor antigens,
as well as other macromolecules, including major histocompat-
ibility antigens (Taylor and Gercel-Taylor, 2011). Exosomes, vs.
microvesicles, have been defined, based on size (30–100 nm lipid
bilayer vesicles), density (1.12 g/ml for B cell derived to 1.19 g/ml
for intestinal cell derived) and expression of specific biomarkers
(including tetraspanins) (Théry et al., 2009). Extracellular vesi-
cles can be viewed as cytoplasm enclosed in a lipid layer with
the external domains of transmembrane proteins exposed to the
extracellular environment in their normal cellular orientation.
Electron microscopic studies have demonstrated the fusion of the
limiting membrane of MVB with the plasma membrane as well as
release of ILVs in different cell types of hematopoietic origin, such
as Epstein-Barr virus (EBV)-transformed B cells (Zumaquero
et al., 2010), mastocytes (Admyre et al., 2008), dendritic cells
(Montecalvo et al., 2008), platelets (Rak, 2010), macrophages
(Anand, 2010) and cells of non-hematopoietic origin like neurons
and epithelial cells (Kesimer et al., 2009).
The exact mechanisms by which cells release exo-
somes/microvesicles remain unclear; however, the release is
modulated by extracellular signals (Ostrowski et al., 2010). Three
primary mechanisms have been proposed for the release of
cellular components into the extracellular space: (1) exocytic
fusion of multivesicular bodies (MVBs) resulting in “exosomes,”
(2) budding of vesicles directly from the plasma membranes
resulting in shed “microvesicles” and (3) cell death leading to
apoptotic bodies. The first two mechanisms are properties of
viable cells and are energy requiring events. While most isolation
protocols readily exclude apoptotic bodies, current methods do
not differentiate extracellular vesicles from the endocytic pathway
from shed “microvesicles” from the plasma membrane. As a
result, most studies on these extracellular vesicle populations
include a mixture of exosomes and microvesicles, which may
confuse interpretation of biochemical data.
Since the formation of exosomes has an endocytic origin, this
mechanism is a process of the endosomal pathway, including
endocytic vesicles, early endosomes, late endosomes and lyso-
somes. The endocytic vesicles are formed through either clathrin-
or non-clathrin-mediated endocytosis at the plasma membrane
and are transported to early endosomes (Yu et al., 2006; Valapala
and Vishwanatha, 2011). The late endosomes develop from early
endosomes via acidification, changes in their protein content
and their ability to fuse with vesicles or other cellular mem-
branes. Early endosomes are localized near the outer margin of
the cells and exhibit a tubular appearance, in contrast late endo-
somes are localized proximal to the nucleus and are spherical
in shape. An essential step in MVB formation from late endo-
somes is reversed budding. In this step, limiting membranes of
late endosomes “bud” into their lumen, resulting in a contin-
uous enrichment of internal luminal vesicles (Yu et al., 2006).
MVBs have been demonstrated to be involved in the exocytic
fusion of their external membrane with the plasma membrane
of the cell, resulting in release of their segregated vesicles to the
extracellular space. Within the vesicles, two invaginations occur,
such that the membrane orientation of proteins within the vesi-
cles is the same as the plasma membrane of the cell. The release
of large biomolecules through the plasma membrane can occur
through the process termed exocytosis, which has regulatory and
signaling functions. Exocytosis can be either constitutive (non-
calcium-triggered) or regulated (calcium-triggered) (Yu et al.,
2006; Valapala and Vishwanatha, 2011). Constitutive exocyto-
sis occurs in all cells and serves to secrete extracellular matrix
components or to incorporate newly-synthesized proteins into
the plasma membrane following fusion with transport vesicles.
Regulated exocytosis is critical to events, such as neurologic sig-
naling, as synaptic vesicles fuse with themembrane at the synaptic
cleft (Graner et al., 2009).
Extracellular vesicles isolated from the extracellular environ-
ment of tumors (such as from the peripheral circulation), either
in vitro or in vivo, exhibit overlapping similarities in size (defined
by dynamic light scattering), morphology (defined by electron
microscopy), density (defined by of sucrose gradient centrifuga-
tion), and protein markers of both the endosomes and plasma
membranes (defined by western immunoblotting and mass spec-
trometry) (Graner et al., 2009; Mathivanan and Simpson, 2009;
Xiao et al., 2012). While many of the definitions are still used, we
now recognize their flaws (Table 1). The apparent size and shape
of exosomes appear to be artifacts of fixation and drying asso-
ciated with electron microscopy. Principal markers of exosomes
are tetraspanins, which as plasma membrane associated compo-
nents are present on most vesicles, regardless for their origin. The
importance of the endocytic pathway of vesicle formation has
also been questioned as knock-out studies with Rab proteins only
diminished vesicle release by ∼30% (based on exosomal protein)
(Peinado et al., 2012).
We have compared the extracellular vesicle populations
obtained from biologic fluids of ovarian cancer patients by
both the technique described to isolate extracellular vesicles and
our original chromatographic method isolating “microvesicles”
(Taylor and Gercel-Taylor, 2005) (Figure 1). This comparative
study demonstrated that these in vivo derived vesicles from both
techniques isolated cup-shaped vesicles, with a density between
1.13 and 1.17 g/ml, a diameter between 50 and 150 nm, and
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Table 1 | Glossary of extracellular vesicle terms.
Term Current definition (Théry et al., 2009) Deficiencies
Exosomes Size: 50–100 nm
Shape: Cup shaped
Sedimentation: 100,000 × g
Markers: Tetraspanins (CD63/CD9), Alix, TSG101, ESCRT
Lipids: Cholesterol, sphingomyelin, ceramide, lipid rafts,
phosphatidylserine
Origin: Multivesicular endosomes
Size and shape may be altered by the fixation process
Tetraspanins are also plasma membrane markers and are not
specific for vesicles derived from MVB
Knockout studies suggest MVB-derived vesicles represent only a
portion of the 50–200 nm vesicles
Lipid composition is also shared with “micromaps” of the plasma
membrane
Microvesicles Size: 100–1000 nm
Shape: Irregular
Sedimentation: 100,000 × g or 10,000 × g or 1200 × g
(dependent on size)
Markers: Intergins, selectins, CD40 ligand
Lipids: Phosphatidylserine
Origin: Plasma membrane
Most circulating vesicles fall in the range of 50–200 nm. In vivo,
larger vesicles are generally not observed
Impossible to distinguish 50–200 nm microvesicles from
exosomes based on sedimentation
Microvesicles derived from surface “micromaps” shared lipid and
protein compositions with exosomes
Tetraspanins can be detected on vesicles of all size ranges
Microvesicle- “specific” markers were demonstrated on vesicles
derived from B cells, thus these may not be relevant to those
derived from other cell types
Apoptotic bodies Size: 400–1000 nm
Shape: Heterogeneous
Sedimentation: 100,000 × g or 10,000 × g or 1200 × g
Markers: Histones
Lipids: Not determined
Origin: Plasma membrane
Exosomes and microvesicles are the products of viable, healthy,
proliferating cells, while apoptotic bodies are released as part of
apoptotic cell death
Exosomes and microvesicles exhibit high degrees of selectivity in
cargoes, while apoptotic bodies contain debris of the dying cell
FIGURE 1 | Example of the isolation of extracellular vesicles from an
ovarian cancer patients using size exclusion chromatography on
Sepharose 2B. Insert shows an electron micrograph of the void volume
material, demonstrating the presence of 50–150nm vesicles.
expressing CD63, Alix, VPS35, galectin 3, HSP90, fibronectin, and
placental alkaline phosphatase (Taylor and Gercel-Taylor, 2005;
Taylor et al., 2011). While patient-derived circulating extracellu-
lar vesicles fit within the definition of exosomes, the contribution
of these two populations is unclear. Since both populations exist
within the peripheral circulation of cancer patients, this distinc-
tion between exosomes and shed microvesicles may not be critical
to understand the biologic activities of these vesicles as they can
interact with target cells of the host as a mixture. In a subse-
quent study comparing methods, we further described a more
uniform vesicle size and superior recovery of vesicle components
(proteins andRNA) by chromatography vs. centrifugation (Taylor
et al., 2011). This advantage of the chromatographic approach
may relate to the fact that vesicles are not subjected to shearing
force associated with centrifugation.
The increased release of extracellular vesicles and their accu-
mulation appear to be important in themalignant transformation
process. Although shedding of extracellular vesicles occurs in
other types of cells under specific physiological conditions, the
accumulation of extracellular vesicles from tumor cells is aug-
mented in biologic fluids. Recently, circulating vesicles of normal
individuals, patients with benign ovarian disease and patients
with ovarian cancer have been investigated using the Nanoparticle
TrackingAnalysis system (NanoSight) (Gercel-Taylor et al., 2012).
The presence of circulating vesicular materials was demonstrated
in all individuals; however, ovarian cancer patients exhibit ∼3–
4-fold more vesicular material. In these cancer patients, the size
range of these vesicles was between 50 and 250 nm, with the major
peak at 98–99 nm.
CARGOES OF EXTRACELLULAR VESICLES
Extracellular vesicles contain proteins, non-coding RNAs, and
mRNAs, and the exosomal lipid bilayer appears to protect these
materials from degradation. While protein and RNA cargoes of
extracellular vesicles vary depending on the originating cell, there
are conserved proteins among extracellular vesicles from differ-
ent cellular origins (Mathivanan and Simpson, 2009). The protein
composition of extracellular vesicles has been extensively analyzed
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by various techniques including Western blotting, fluorescence-
activated cell sorting, immuno-electron microscopy and mass
spectrometry. All extracellular vesicles exhibit cytoskeleton pro-
teins (such as ezrin and actins), proteins associated with the
MVB biogenesis (such as alix and TSG101), membrane trans-
port and fusion proteins (e.g., annexins and Rab proteins), and
tetraspanins (e.g., CD9, CD63, and CD81). A catalog of pro-
teins, RNAs, and lipids assoicated with extracellular vesicles can
be found at www.exocarta.org. Currently, ExoCarta lists entries
for 13,333 proteins, 2375 mRNAs, 764 microRNA, and 194 lipids
associated with extracellular vesicles.
We have analyzed the patient-derived exosomal proteome
using ion trap mass spectrometry and identified 232 unique
proteins. These proteins were classified as percent of the iden-
tified total proteins into molecular chaperones (8.5%), vesicle
fusion (8.5%), cytoskeletal proteins and proteins involved in
the assembly/disassembly of the cytoskeletal networks (17.6%),
anionic and cationic ion transport channels (3.7%), proteins
involved in lipid (6.9%), carbohydrate (3.2%) and amino-
acids (2.1%) metabolisms, proteins involved in DNA replication
(6.9%), mRNA splicing (5.3%), transcription/translation (5.3%),
post-transcriptional protein modification (13.8%), and signal
transduction (2.7%). Our studies demonstrated that cytosolic
proteins were highly represented and we observed a diverse array
of cytoskeletal constituents (actin, α-actinin-1, cofilin, filamin-
A-B-C, tubulins, gelsolin, profilin-1, spectrin, symplekin, talin,
vinculin, myosins). We identified that transmembrane proteins
were also abundant, including multiple integrins (β1, α3, αv),
intercellular adhesion molecule 1 (ICAM-1), and mucin-4. A
variety of channels were observed, such as the voltage-dependent
anion-selective channel protein 2 and 3, chloride intracellular
channel protein 1, sodium/potassium-transporting ATPase sub-
unit β-3, long of sodium/potassium-transporting ATPase sub-
unit α-1, and transitional endoplasmic reticulum ATPase. In
line with their endocytic origin, exosomal proteins belonging
to the ESCRT complex that are important protein complexes
involved in ubiquitin-dependent exosome biogenesis, have also
observed (Doring et al., 2010). These ESCRT-associated proteins
include vacuolar protein sorting-associated protein 35 (VPS-35),
Alix, ubiquitin-like modifier-activating enzyme and ubiquitin
carboxyl-terminal hydrolases. We demonstrated that proteins
involved in membrane trafficking and fusion processes were
enriched (annexin A2, A5, A6, clathrin heavy chain 1/2, coatomer
subunit β, Rab1b, Rab2a, and Rab7a). A group of markers of
endosomes and lysosomes were also detected (cathepsin-C, D, EH
domain-containing protein 1 and β-hexoaminidase), and several
chaperonnes were identified (HSP70, HSP90, HSC70, HSPA4,
8, 9, HSPA1A/B, HSPB1, HSP47, HSPA5, HSPβ1, HSPD1,
HSP90AB1, B1, AA1; T-complex protein 1, endoplasmin, and
protein disulfide-isomerase A3, A4, A6) (Graner et al., 2009;
Mathivanan and Simpson, 2009).
EXTRACELLULAR VESICLE-ASSOCIATED RNA
The current hypothesis for the stability of circulating RNA is
that they are released from cells in membranous vesicles. Recent
data confirm that extracellular RNA can exist in four forms: free
RNA, Argonaut 2-bound RNA, high-density lipoprotein-bound
RNA and vesicle-associated RNA. This review focuses on RNA
associated with extracellular vesicles. These extracellular vesi-
cles are generated constitutively by most, but not all, cell types
and contain both mRNAs and non-coding RNA. The ability of
extracellular vesicles to transfer genetic information may facili-
tate cancer spread by delivering genetic material and oncogenic
proteins. RNA profiles of extracellular vesicles differ from that of
cellular RNA, since vesicles contain primarily small RNA, such as
mRNA and microRNA, in the absence of ribosomal RNA (Skog
et al., 2008; Taylor and Gercel-Taylor, 2008).
The presences of circulating RNAs have been extensively inves-
tigated, despite the presence of highly stable RNases, which should
degrade any free RNA. The majority of the circulating RNAs
have been defined as microRNAs based on the molecular weight
(Mitchell et al., 2008). Studies also demonstrated that microR-
NAs not only have high stability in body fluids, but also survive in
the unfavorable physiological conditions such as freeze-thawing,
extreme variations in pH and long time at room temperature
(Mitchell et al., 2008; Duggagupta et al., 2011; Chen et al., 2012).
Whereas adding detergents, such as Triton X or SDS, to serum or
plasma makes microRNAs easily degradation by RNases (Zhang
et al., 2010). The results indicate there are at least two approaches
responsible for the stability of extracellular microRNAs: be pack-
aged in membrane-encapsulated vesicle and be protected by
RNA-binding proteins.
The stability of extracellular microRNAs has been hypothe-
sized to be due to the formation of the RNA-vesicle. During RISC
disassembly in the cytoplasm, some microRNAs are found to
be sorted into MVBs, which are commonly considered to form
exosomes by fusion with the plasma membrane (Simons and
Raposo, 2009). Both exosome andmicrovesicle can easily translo-
cate across the cell membrane, which makes microRNAs enter
recipient cells easily and mediate cell-to-cell communication.
Our studies have indicated that many of RNAs enriched
in the extracellular vesicles may not be abundant, or even
detectable, in the originating cell or highly expressed within
the cell and low or absent within extracellular vesicles (Gercel-
Taylor et al., 2013), indicating sorting of specific RNAs into
extracellular vesicles. These released microRNAs can be clas-
sified in three categories based on the ratio between the
amount of microRNA released from the cells and the amount
retained in the cell (Pigati et al., 2010). The first group is
selectively released microRNAs, which are characterized by
being primarily released from tumor cells with relatively low
concentrations remaining in the cell. In contrast, normal
cells do not release appreciable quantities of these microR-
NAs (Pigati et al., 2010). An additional group of released
microRNAs are those released in equal levels as they appear
within the cell, termed neutrally released microRNA. These
neutrally released microRNAs include miR16 and miR21,
where the abundance in extracellular vesicles reflects increased
abundance in the tumor cells. The selectivity of release
of specific microRNAs differs depending on the cell type
(Rabinowits et al., 2009; Pigati et al., 2010; Mittelbrunn et al.,
2011). Selectivity appears to be influenced by malignant transfor-
mation. Breast and ovarian tumor cells have been demonstrated
to release >99% of miR451 and miR1246 produced by the cells
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(Pigati et al., 2010; Gercel-Taylor et al., 2013). These selectively
released microRNAs have been linked to the malignant pheno-
type. MiR451 has been identified as a tumor suppressor, defining
proliferation and cell polarity. miR451 has also been shown to
induce chemosensitivity. miR1246 induces p53-dependent apop-
tosis triggered by DNA damage (Zhang et al., 2011). The changes
in the release of cancer-related microRNAs may suggest a role for
selective microRNA export in malignant transformation, and it
may provide a cancer signature within the exported, circulating
microRNA population.
While the mechanism of this selective sorting is unclear,
some have postulated this selectivity relates to microRNA/RNA-
induced silencing complex (RISC) components. Extracellular
vesicles contain components of the microRNA/RISC, such as
Argonaut 2, together with several RNA-binding proteins known
to regulate RNA traffic between the nucleus and the cytoplasm.
It can be therefore hypothesized that, during vesicle biogene-
sis, these RNA binding proteins regulate the accumulation of
selected RNAswithin extracellular vesicles. Studies on the transfer
of reporter mRNAs and their translation into proteins, demon-
strated both in vitro and in vivo, suggest that the mRNA delivered
by extracellular vesicles is functional (El-Andaloussi et al., 2012;
Tetta et al., 2013).
Extracellular vesicles derived from other tumors such as col-
orectal (Silva et al., 2012), lung (Rabinowits et al., 2009), and
prostate cancer cells (Bryant et al., 2012) alter the phenotype
of normal cells by transferring specific RNA subsets. In con-
trast, extracellular vesicles released from the surrounding cells
may modify cancer cell gene expression (Bryant et al., 2012).
Extracellular vesicles derived from cancer stem cells were shown
to contain pro-angiogenic RNAs able to induce a pre-metastatic
niche in the lungs, whereas those derived from differentiated can-
cer cells were not able to induce this niche and their mRNA
and microRNA content differs (Grange et al., 2011). Extracellular
vesicles from cancer stem cells contained miR29a, miR650, and
miR151, all associated with tumor invasion and metastases, along
with miR19b, miR29c, and miR151, known to be up-regulated in
patients with renal carcinomas (Grange et al., 2011).
Extracellular vesicles have been isolated and analyzed from
both normal healthy individuals and patients with various
physiological conditions. We have previously shown that can-
cer patients (Gercel-Taylor et al., 2012) and pregnant women
(Atay et al., 2011a) exhibit more extracellular vesicles in their
blood compared to their normal, healthy counterparts. In preg-
nant women, the extracellular vesicles are thought to play a role
in the maternal-fetal tolerance occurring during pregnancy, as
it has been shown that placenta extracellular vesicles suppress T
lymphocytes (Atay et al., 2011b).
Most investigations on small RNAs in exosomes have been lim-
ited to microRNA; however, next generation sequencing small
RNAs in extracellular vesicles is expanding the populations
identified. While intracellular microRNAs have been defined in
many biological processes, identification of extracellular vesicle-
associated microRNAs represents a non-invasive approach to
investigate disease-specific microRNA and may provide a method
for disease diagnosis (Duggagupta et al., 2011). To detect, ana-
lyze, and quantitate the RNA signatures of exosomes derived
from biologic fluids, several approaches have been used, includ-
ing microarrays, quantitative real-time PCR, and next-generation
sequencing. The development of high detection sensitivity in next
generation sequencing technologies has expanded the identifica-
tion of the exosomal transcriptome, beyond miRNA. While most
studies have focused on exosomal microRNAs, we now recognize
the presence of numerous other small RNAs within these circu-
lating exosomes, as well as fragments of larger RNAs (Figure 2).
These exosomal small non-coding RNAs are<200 nucleotides in
length (generally are 20–30 nt). There are three primary popu-
lations of small non-coding RNAs, including siRNAs, miRNAs,
and piRNAs. Small non-coding RNAs have been shown to be
key regulators in development, apoptosis, stem cell self-renewal,
differentiation, and cell integrity maintenance. Piwi-interacting
RNAs (piRNAs) are generated from intergenic elements, includ-
ing transposable elements, through Dicer-independent pathways.
These piRNAs function through the Piwi-Argonaute sub-family
(AGO3, Aubergine, and Piwi), leading to silencing of trans-
posable elements. A link between piRNAs and cancer has been
FIGURE 2 | The distribution of small RNAs derived from circulating extracellular vesicles of normal controls vs. ovarian cancer patients, based on
next generation sequencing.
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demonstrated in gastric cancers where two aberrantly expressed
piRNAs, piRNA-651 and piRNA-823, were found in gastric tumor
tissue vs. paired normal tissue (Cheng et al., 2011, 2012).
FUNCTIONS OF EXTRACELLULAR VESICLES
While some early studies implicated extracellular vesicles as
“garbage bags” of the cells (Pan et al., 1983; Johnstone et al.,
1987), the vesicles released from tumor cells have gained increas-
ing recognition as “vehicles” for intercellular communication.
Intercellular communication has been thought to be limited to
cell-to-cell adhesion conduits (gap junctions) or secreted signals,
such as hormones, neurotransmitters, and cytokines, released
from cells and acting in an autocrine or paracrine manner. These
extracellular vesicles interact with the plasma membrane of a
recipient cell by ligand/receptor binding, fusion or internaliza-
tion (or a combination of these, Figure 3). If the extracellular
vesicles fuse with the target cell, they can transfer their cargo
to that recipient cell. Due to the presence of cell-type specific
adhesion molecules, extracellular vesicles can interact with spe-
cific cells and deliver their “cargoes,” including bioactive lipids,
cytokines, growth factors, receptors and genetic materials. In this
manner, extracellular vesicles represent a pathway for intercellu-
lar transfer of information, similar to that observed with direct
cell–cell contact, but that can function at distance. Extracellular
vesicles provide stable conformational conditions for their pro-
tein content, conserve bioactivity of their proteins, improve
bio-distribution and support an efficient interaction with target
cells.
The complexity of extracellular vesicle associated bioactive
macromolecules supports a critical role in generating the tumor
microenvironment (Marhaba et al., 2008; Park et al., 2010).
Extracellular vesicles can transfer specific proteins to target cells
for the delivery of signaling pathways (Hong et al., 2009; Xiang
et al., 2009). The presence of tumor-derived extracellular vesi-
cles can increase matrix metalloproteinase (MMP) secretion and
VEGF expression in target cells through the expression of pro-
angiogenic molecules, such as members of the tetraspanin family,
thereby promoting neo-angiogenesis even at secondarymetastatic
sites (Nazarenko et al., 2010). The released MMPs can digest
the extracellular matrices where they arise. This degradation is
FIGURE 3 | Scheme of the potential mechanisms of interactions
between an extracellular vesicle and a target cells. The interactions
include receptor/ligand binding, fusion, and internalization.
enhanced when MMPs are co-released with exosome-associated
extracellular MMP inducer (EMMPRIN) (Keller et al., 2009).
Studies have shown that cancer ascites-derived extracellu-
lar vesicles carry extracellular matrix-remodeling enzymes, such
as metalloproteinases 2 and 9 (MMP-2, MMP-9) (Dolo et al.,
1999a,b), and urokinase plasminogen activator (Graves et al.,
2004), leading to an increase in extracellular matrix degrada-
tion. The expression of matrix-remodeling enzymes increases the
tumor’s invasive phenotype and promotes metastasis. The pres-
ence of pro-angiogenic factors supports neovascularization of the
developing tumor. A commonly identified cellular component
of the tumor microenvironment is the monocyte/macrophage.
Within the microenvironment, tumor-associated macrophages
have been shown to assist in tumor progression by expressing
cytokine/chemokine profiles that promote angiogenesis, stimu-
late tumor growth, and elicit immunosuppression by suppressing
Th1 responses (Lewis and Pollard, 2006; Whiteside, 2013). The
tumor microenvironment is characterized by pro-inflammatory
profiles, including interleukin-1β (IL-1β). This profile is gen-
erally produced by infiltrating macrophages following interac-
tions with tumors or their components. While we proposed
that extracellular vesicles could “educate” macrophages to pro-
duce pro-inflammatory cytokines following internalization, we
recently demonstrated that the induction of IL-1β was observed
even when internalization of vesicles was blocked (Atay et al.,
2011a,b). RGD peptides, which are used to block fibronectin
binding to macrophage α5β1 integrin, were observed to abrogate
vesicle-induction of IL-1β production and down-stream phos-
phorylation of Akt and c-Jun (Atay et al., 2013). This approach
reveals the importance of receptor/ligand interactions in vesicle
communication.
Extracellular vesicles can be internalized by recipient cells fol-
lowing receptor-ligand interactions and the varied assortment of
bioactive molecules, derived from the cell of origin, such as pro-
teins, bioactive lipids, and nucleic acids, can be transferred along
with the proteins expressed on the vesicle surface. Extracellular
vesicles may directly activate the recipient cell by acting as signal-
ing complexes (Corrado et al., 2013; Ji et al., 2013). Extracellular
vesicles derived from macrophages bind to platelets by means
of the P-selectin glycoprotein ligand-1 expressed on their sur-
face and extracellular vesicles from neutrophils expressing Mac-1
may induce platelet activation (Brouckova and Holada, 2009).
Extracellular vesicles may also transfer receptors from one cell to
another. Bystander B cells have been shown to rapidly acquire
antigen receptors from activated B cells by membrane transfer
with the resulting increase of a cell population presenting a spe-
cific antigen to CD4 T cells (Quah and O’Neill, 2005). Also,
Fas ligand can be transferred from tumor cells by extracellu-
lar vesicles provoking activated T cell apoptosis (Teng et al.,
2012). Moreover, extracellular vesicles may convey proteins to
the cytoplasm of recipient cells, such as the cell death caspase-1
message conveyed by microvesicles derived from LPS-stimulated
monocytes (Dubyak, 2012), or the tumor exosome-carried Notch
ligand Delta-like 4 which inhibits Notch signaling, enhancing
angiogenesis (Sheldon et al., 2010).
When released extracellular vesicles fuse with their target
cells, they can transfer specific membrane components, including
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receptors and ligands, which can express an activated pheno-
type. This transfer of receptors from extracellular vesicles to target
cells was demonstrated by the observation that bystander B cells
acquire antigen receptors from activated B cells by membrane
transfer (McLellan, 2009). This transfer allows the amplified
expansion of antigen-binding B cells with the ability to present
specific antigens to CD4 T cells. Extracellular vesicles can transfer
the adhesion molecule CD41 from platelets to endothelial cells
or to tumor cells, conferring pro-adhesive properties to the tar-
get cell (Ratajczak et al., 2006). Exosome-mediated transfer of
Fas ligand from tumor cells induces apoptosis of activated T cells
enabling tumor immune escape (Ichim et al., 2008). Extracellular
vesicles can also be protective for tumor cells by removing
molecules, such as Fas or the membrane attack complex, from
their membranes.
The horizontal transfer of macromolecules and their func-
tional consequences has been demonstrated in human gliomas
(Al-Nedawi et al., 2008, 2009a). In this model, only a fraction
of the cells, exhibiting a transformed phenotype, expressed the
truncated epidermal growth factor receptor, EGFRvIII, associ-
ated with dysregulaed tumor growth (Al-Nedawi et al., 2009b).
Al-Nedawi et al. (2008) demonstrated transfer of the oncogenic
EGFRvIII from human glioma cancer cells expressing the receptor
to glioma cells without the EGFRvIII via the fusion of extracellu-
lar vesicles. After transfer, the glioma cells, lacking the receptor,
were transformed to express EGFRvIII-regulated genes, includ-
ing VEGF, Bcl-xL, and p27 (Al-Nedawi et al., 2009a). Subsequent
studies demonstrated that the oncogenic EGFRvIII from human
squamous cell carcinoma cells was transferred via extracellular
vesicles to tumor-associated endothelial cells to activate MAPK
and Akt cell signaling pathways and promote endothelial VEGF
expression (Al-Nedawi et al., 2009b).
Epigenetic changes have been frequently demonstrated in
various tumors, resulting in regulation of gene transcription,
altered proliferation, differentiation, and therapeutic resistance
(Viswanathan et al., 2003; Camussi et al., 2010). Genetic infor-
mation can be transferred through two proposed mechanisms:
vertical gene transfer, gene exchange from parent to the next
generation, and horizontal gene transfer, induced through, for
example, bacteriophages or viruses. Since extracellular vesicles
have been implicated as a potent source of macromolecule
transfer to neighboring and distant cells, viruses and other
pathogens appear to exploit this system. Extracellular vesi-
cles are postulated to contribute to the spread of infective
agents, such as human immunodeficiency virus type 1 (Lenassi
et al., 2010). In macrophages receiving chemokine receptors,
this can induce an increased risk of HIV infection together
with resistance to apoptosis. The transfer of the chemokine
(CXC motif) receptor 4 and the chemokine (CC motif) recep-
tor 5 chemokine co-receptors for human immunodeficiency
virus type I by released extracellular vesicles can enhance the
entry of the virus into cell types other than the lympho-
hemopoietic lineage (Izquierdo-Useros et al., 2009). In addi-
tion to transferring receptors, extracellular vesicles can transfer
viruses, contained within extracellular vesicles, by the “Trojan
exosome hypothesis” involving direct delivery (Izquierdo-Useros
et al., 2010).
Cell-derived extracellular vesicles represent another mecha-
nism of horizontal gene transfer. Genomic instability may be
mediated by horizontal transfer of tumor-derived materials via
extracellular vesicles. Horizontal transfer of macromolecules,
including RNA, proteins and lipids, via extracellular vesicles has
been shown in a multiple tumor systems, including: gliomas,
monocytes, mast cells, and T cells (Skog et al., 2008). Tumor-
derived extracellular vesicles have been shown to be capable of
transferring surface components (proteins and lipids) and RNAs
to monocytes. Janowska-Wieczorek et al. (2005) demonstrated
that extracellular vesicles derived from murine embryonic stem
cells (ESCs) could induce epigenetic reprogramming of target
cells. ESC-derived extracellular vesicles were shown to improve
survival of hematopoietic stem/progenitor cells, to induce up-
regulation of early pluripotent and early hematopoietic mark-
ers, and to induce phosphorylation of mitogen-activated protein
kinase p42/44 and Akt. ESC-derived extracellular vesicles were
shown to express mRNAs for several pluripotent transcription
factors that can be delivered to target cells and translated to their
corresponding proteins (Koh et al., 2010). As RNase-treatment
inhibited their exosome-mediated biological effect, the involve-
ment of mRNA in the observed biological effects was suggested.
Yuan et al. (2010) have shown that in addition to mRNA, extra-
cellular vesicles can transfer microRNA to target cells. They
demonstrated that extracellular vesicles derived from ESCs con-
tain abundant microRNA and that they can transfer a subset
of microRNAs to mouse embryonic fibroblasts in vitro. Since
microRNAs are regulators of protein translation, this observa-
tion raised the possibility that stem cells can alter the expression
of genes in neighboring cells by transferring exosomal microR-
NAs. When shed vesicles fuse with their target cells, the portion
of cytosol segregated within their lumen is discharged to and inte-
grates with the cytosol of the target cell. Because this transfer can
also include transmission of specific mRNAs, it can ultimately
contribute to the epigenetic and proteomic properties of target
cells.
Extracellular vesicles have been proposed to re-model and
educate the host environment to generate a favorable niche for
tumor growth, invasion and spread of metastasis (Peinado et al.,
2012). Extracellular vesicles from lung cancer cells can acti-
vate the expression of pro-angiogenic factors, including IL-8,
VEGF, LIF, oncostatin M, IL-11 and MMP 9 in adjacent stromal
cells, “educating” the microenvironment to support lung cancer
cell metastasis (Kucharzewska et al., 2013). Extracellular vesicles
released by tumors have been shown to have immunosuppres-
sive functions, including the suppression of both T lymphocytes
and natural killer cell activation (Abusamra et al., 2005; Ashiru
et al., 2010). It has also been suggested that tumor cell extra-
cellular vesicles can migrate to the lymph nodes and condition
them to become more favorable environments for metastasis
(Rana et al., 2013). Recent studies demonstrate that the extracel-
lular vesicles target specific organs and their presence can initiate
organ tropism of metastases. It has been postulated that microR-
NAs delivered by extracellular vesicles play a role in immune
system regulation. An extracellular vesicle-dependent exchange
of microRNAs between APC and T cells occurs at the site of
immune synapses (Gutiérrez-Vázquez et al., 2013), including the
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exchange of genetic information between DCs and T cells through
extracellular vesicles (Mittelbrunn et al., 2011).
It has been suggested that tumor cell progression could use
multiple forms of extracellular vesicle-mediated communication
to simultaneously affect multiple effector populations, based
on release of tissue factors, immunoregulators and oncogenic
molecules. Thus, the signals transferred to neighboring and dis-
tant cells via extracellular vesicles may mirror the transcriptional
status of the parent cell, but due to the exosomal messenger
RNA andmicroRNA being transferred, their consequences on the
translational machinery of the target cells are extensive.
DIAGNOSTIC APPLICATION OF RNA WITHIN
EXTRACELLULAR VESICLES
There are two critical roadblocks for successful long-term sur-
vival of patients with cancer. First, there are no clinically useable
markers to identify early stage cancers in asymptomatic individ-
uals or to differentiate benign from malignant disease. Second,
there are no methods to evaluate the dynamic changes in tumors
during therapy. Standard imaging approaches do not provide
metrics of tumor-specific genetic/phenotypic changes and opera-
tive information is expensive, potentially morbid and limited by
errors in topographic sampling. Lacking metrics, clinicians are
left unable to target appropriate therapy to tumors in individual
patients. This seriously compromises the development of novel
effective therapies in addition to effective and improved use of
current modalities. Circulating biomarkers have been proposed
to be promising for the definitive diagnosis and monitoring treat-
ment of various tumor types. Defining tumor-specific biomarkers
has numerous advantages, such as diagnosing the disease, iden-
tifying processes that are difficult to image, predicting outcome
by identifying patients at risk for therapeutic failure, defining
tumor-specific molecular and pathological alterations for devel-
oping therapeutic targets and monitoring responses to acute
interventions (Kim et al., 2013). Such circulating biomarkers
could also serve to monitor disease progression and predicting
risk of recurrence; however, circulating biomarkers are problem-
atic and exhibit several critical issues. Free protein and nucleic
acid biomarkers are extremely unstable in the circulation, thus
to detect these, a high steady-state must be reached for detec-
tion, which is generally not observed except in late stage disease,
minor changes over time (essential for monitoring) are difficult
to quantify and these biomarkers are sensitive to sample handling.
The use of exosome-associated biomarkers appears to be capable
of circumventing these issues. These tumor-derived extracellular
vesicles are extremely stable within the circulation, in the order of
days (vs. minutes for soluble markers). In addition to serving as
biomarkers of cancer, data demonstrate that these tumor-derived
exosomes may mediate events associated with tumor progression
and metastases.
Exosomes provide stable, disease-specific markers for detec-
tion, disease characterization, and predicting prognosis (Liang
et al., 2013). Temporal changes in exosomal RNA profiles have
been demonstrated to accurately predict disease recurrence and
overall patient survival (Takeshita et al., 2013). The proteomic
and genomic profiles of circulating exosomes provide a real-
time monitor of therapeutic response, serving as a companion
diagnostic. By correlating these circulating markers with the
molecular characteristics and real-time clinical parameters, he has
established the use of circulating exosomes as a “liquid biopsy.” In
2008, we published the initial demonstration of circulating exo-
somal RNA for their diagnostic use (Taylor and Gercel-Taylor,
2008). Since that time, many studies have examined the diag-
nostic utility of profiling total circulating microRNA in specific
pathologies; however, no study, to date, has defined circulat-
ing exosome microRNA signatures derived from a single cell
type. The release of exosomal RNAs exhibit features for util-
ity as diagnostic biomarkers, as they can be detected at early
stages, are present in routinely obtained biologic fluids (blood,
CSF, urine, and saliva), are specifically derived from the cancer
tissue, and can be easily and accurately quantified. Studies have
demonstrated that extracellular vesicles are enriched in tumor-
derived bioactive molecules. The level of extracellular vesicles in
the peripheral blood of healthy controls has been observed to
be ∼1010/ml of blood and may increase 3–4 fold in patients with
cancer.
One issue for the use of extracellular vesicles as diagnostic
markers is that they are also released by other cells associated
with the peripheral blood, including lymphocytes, platelets, and
endothelial cells. This has established the need for isolation of
specific vesicles populations, To address this, in our initial study,
extracellular vesicles of tumor origin were isolated from the blood
of women with ovarian cancer using antibodies reactive with
epithelial cell adhesion molecule (EpCAM). It was also shown
that the level of circulating EpCAM-positive extracellular vesi-
cles increased with disease progression (Taylor and Gercel-Taylor,
2008). Furthermore, eight microRNAs previously shown to be
overexpressed in ovarian cancer were demonstrated to be present
in both the tumors and the serum extracellular vesicles with a
strong correlation in expression levels. This suggests that the exo-
somal RNA can be used to characterize the tumor without having
to obtain biopsies of the tumor. A significant increase in the lev-
els of the eight microRNAs was also seen in extracellular vesicles
from patients with ovarian cancer, compared to the benign sam-
ples. This study demonstrated for the first time that the RNA
in extracellular vesicles could be used as a diagnostic marker for
cancer and importantly, it could be used to distinguish benign
vs. malignant tumors (Taylor and Gercel-Taylor, 2008). A year
later, similar results demonstrated that the microRNA in serum
extracellular vesicles from lung cancer patients could be used
as a diagnostic marker (Rabinowits et al., 2009). It was shown
that patients with lung cancer also had more EpCAM-positive
extracellular vesicles in their serum, compared to controls. The
levels of 12 microRNAs previously found in lung tumor biop-
sies were detected in both the serum extracellular vesicles and
the tumors. Again, a strong correlation in microRNA expres-
sion was found between these two sources (Rabinowits et al.,
2009). These two studies showed that exosomal microRNAs,
while exhibit some unique features, are generally representative
of the tumor, suggesting that instead of biopsies, serum extracel-
lular vesicles could be a relatively non-invasive route to profile a
tumor.
The RNA content of serum extracellular vesicles from glioblas-
toma patients has also been investigated for its potential role
as a biomarker. Skog et al. (2008) demonstrated mutated ver-
sion of the epidermal growth factor receptor (EGFR) mRNA,
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EGFRvIII, detected in 47% of the tumors in glioblastoma patients,
could also be detected in serum-derived extracellular vesicles in
28% of the patients. This mRNA was not detected in the serum
extracellular vesicles from healthy controls. After surgical removal
of the tumor, the mRNA could no longer be detected in the
patients’ peripheral circulation, demonstrating the tumor as the
source of the extracellular vesicles (Skog et al., 2008). This study
showed that the vesicle-associated mRNA could serve as biomark-
ers, however, the correlation between mRNA expression in the
extracellular vesicles and tumor was weaker than that observed in
microRNA studies. Most critically, this study demonstrated that
mutations in the tumor could be identified within RNA isolated
from extracellular vesicles.
Extracellular vesicles are released by many cells, including
as reticulocytes, dendritic cells, B cells, T cells, mast cells,
macrophages, epithelial cells, and tumor cells (Gallo et al., 2012).
Within mast cell lines, 121 microRNAs, including miR-1, miR-
15, miR-16, miR-17, miR-18, miR-181, miR-375, lin-4 and let7,
were demonstrated within their released extracellular vesicles
(Valadi et al., 2007). Other microRNAs, such as miR223 expressed
in IL-4-activated macrophages, miR451 in dendritic cells and
miR335 in T cells, have been demonstrated in extracellular vesi-
cles from normal cell types (Mittelbrunn et al., 2011; Yang
et al., 2011). Based on these observations, most extracellular
microRNAs within the peripheral circulation are primarily in
extracellular vesicles (Gallo et al., 2012).
CONCLUSIONS
While the use of extracellular vesicles as biomarkers in the clini-
cal setting remains years away, the findings presented within this
review demonstrate their significant diagnostic potential. This
overview of the RNA cargoes of extracellular vesicles reveals their
ability to distinguish benign ovarian tumors from malignant dis-
ease. Further, we can obtain and analyze the microRNA profiles
of lung and ovarian tumors prior to surgery, we can identify the
mutation status of tumors based on a blood specimen, and we can
predict patient survival and risk of recurrence.
In the 5 years since our initial demonstration of the diag-
nostic utility of RNA profiles from extracellular vesicles, new
and sensitive techniques have been developed, including deep
sequencing and focused microarrays and real time PCR, which
can expand the information from transcriptome from the tumor-
derived extracellular vesicles. The vesicle platform for diagnostics
provides a multiplex approach to studying biomarkers relying on
a single marker. This additional genetic information will extend
the potential of using circulating vesicular RNAs as biomarkers in
diagnostics, but provides biomarkers for with patient stratifica-
tion, selection of personalized therapies, companion diagnostics
and for monitoring therapeutic responses. As early detection
is essential for improved patient survival, the utility of cargo
analyses of extracellular vesicles will be particularly valuable in
identifying asymptomatic patients and stratify patient popula-
tions. WhilemicroRNA expression profiles have been the primary
RNA population investigated, current findings demonstrate the
presence of other RNAs that may be important in malignant
properties linked with progressive cancer. Current and future
studies are addressing the ability of vesicle-associated RNAs to
identify the risk for developing cancer, monitoring its progres-
sion, and predict its prognosis. The development of their vesicular
RNA markers may also serve as valuable tools in companion
diagnostics, for assessing clinical trials and defining therapeutic
options.
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